A detailed history of Convergence Investment Partners, LLC transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Convergence Investment Partners, LLC holds 54,906 shares of CPRX stock, worth $1.15 Million. This represents 0.31% of its overall portfolio holdings.

Number of Shares
54,906
Holding current value
$1.15 Million
% of portfolio
0.31%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 01, 2025

BUY
$21.4 - $26.31 $1.17 Million - $1.44 Million
54,906 New
54,906 $1.19 Million
Q4 2022

Feb 03, 2023

BUY
$12.25 - $19.5 $97,203 - $154,732
7,935 New
7,935 $147,000

Others Institutions Holding CPRX

About CATALYST PHARMACEUTICALS, INC.


  • Ticker CPRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 102,820,000
  • Market Cap $2.16B
  • Description
  • Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...
More about CPRX
Track This Portfolio

Track Convergence Investment Partners, LLC Portfolio

Follow Convergence Investment Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Convergence Investment Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Convergence Investment Partners, LLC with notifications on news.